We are excited to announce that Protective Antigen has been selected as Clovertex’s Target of the...
We are excited to announce that CD38 has been selected as Clovertex’s Target of the Month for June. CD38 is a multifunctional enzyme found on the surface of many immune cells, including plasma cells and natural killer cells. The spotlight on CD38 this month is due to recent news of Biogen's strategic acquisition of Human Immunology Biosciences (HI-Bio), a deal worth $1.15 billion upfront with an additional $650 million in potential milestone payments.
This acquisition enhances Biogen’s immunology portfolio, particularly emphasizing the development of felzartamab, a promising anti-CD38 monoclonal antibody. Felzartamab has already achieved Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for its potential in treating primary membranous nephropathy and antibody-mediated rejection in kidney transplant recipients. With Phase 3 trials on the horizon, this therapy represents a significant advancement in treating these complex conditions.
The Protein Imager rendering displays the crystal structure of HexaBody-CD38 Fab in complex with CD38 (PDB entry 8BYU).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
2. Clovertex website
